All In MedTech

Device Trial Radar · NCT07794306

Balloon- Versus Self-Expanding Intraannular TAVI in Small Aortic Annuli

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

510

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Jul 31, 2028

Study completion Dec 31, 2033

Sponsor

Lead sponsor
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 31, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In Europe TAVI is now recommended for treatment of aortic valve stenosis from the age of 70 years. When performing TAVI in young patients, lifetime management becomes important in terms of anticipated TAVI-in-TAVI procedures when valve deterioration occures. Especially small aortic annuli represent a special challenge in terms of postprocedural hemodynamics, however intra-annular transcatheter heart valve designs should be the devices of choice to facilitate future TAVI-in-TAVI procedures. Which intra-annular valve design offers ideal clinical and hemodynamic efficacy is unclear. Therefore, an investigator-initiated, randomized controlled trial (BALANCE trial: Balloon- vs. Self-expanding intraannular TAVI in small aortic annuli) was created to elucidate this topic.

Conditions

  • Aortic Valve Stenosis

Interventions

  • Meril Octapro+ THV SystemDevice

    TAVI treatment with Meril Octapro+ THV System

  • Abbott Navitor/Navitor Vision THV systemDevice

    TAVI treatment with Abbott Navitor/Navitor Vision System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Safety according to VARC-3 CriteriaTime frame: 30 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Center Hamburg-Eppendorf (UKE), University Heart and Vascular Center Hamburg

    Hamburg, Free and Hanseatic City of Hamburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.